Detalles de la búsqueda
1.
Real-world effectiveness of fremanezumab for the preventive treatment of migraine: Interim analysis of the pan-European, prospective, observational, phase 4 PEARL study.
Cephalalgia
; 43(11): 3331024231214987, 2023 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37987641
2.
Numbers needed to treat or harm and likelihood of being helped versus harmed for fremanezumab in patients who had prior inadequate response to two to four classes of migraine preventive medications: A post hoc analysis.
Headache
; 63(10): 1351-1358, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37955395
3.
Clinical characteristics and patient-reported outcomes of chronic and episodic migraine patients at a US tertiary headache center: A retrospective observational study.
Headache
; 63(7): 908-916, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37314065
4.
Efficacy and quality-of-life improvements with fremanezumab treatment in patients with difficult-to-treat migraine with associated neurological dysfunction.
Eur J Neurol
; 29(7): 2129-2137, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35302681
5.
Improvements in quality of life and work productivity with up to 6 months of fremanezumab treatment in patients with episodic and chronic migraine and documented inadequate response to 2 to 4 classes of migraine-preventive medications in the phase 3b FOCUS study.
Headache
; 61(9): 1376-1386, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34374086
6.
Reversion From Chronic Migraine to Episodic Migraine in Patients Treated With Fremanezumab: Post Hoc Analysis From HALO CM Study.
Headache
; 60(10): 2444-2453, 2020 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-33179323
7.
Improvements across a range of patient-reported domains with fremanezumab treatment: results from a patient survey study.
J Headache Pain
; 21(1): 109, 2020 Sep 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32887548
8.
Adverse Events Reported with Therapies Targeting the CGRP Pathway During the First 6 Months Post-launch: A Retrospective Analysis Using the FDA Adverse Events Reporting System.
Adv Ther
; 40(2): 445-459, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36350532
9.
Comment on: Gao B, Lu Q, Wan R, Wang Z, Yang Y, Chen Z, Wang Z. "Monthly versus quarterly fremanezumab for the prevention of migraine: a systemic review and meta-analysis from randomized controlled trials". Naunyn Schmiedebergs Arch Pharmacol. 2021 Apr;394(4):819-828. Epublished November 2020.
Naunyn Schmiedebergs Arch Pharmacol
; 394(11): 2343-2346, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34581836
Resultados
1 -
9
de 9
1
Próxima >
>>